Aramburo C, Montiel JL, Proudman JA, Berghman LR, Scanes CG. 1992. Phosphorylation of prolactin and growth-hormone. Journal of Molecular Endocrinology 8:183-191.
Arany Z, Elkayam U. 2016. Peripartum Cardiomyopathy. Circulation 133:1397-1409.
Bajou K, et al. 2014. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin (vol 20, pg 741, 2014). Nature Medicine 20:1217-1217.
Baldocchi RA, Tan L, Hom YK, Nicoll CS. 1995. Comparison of the ability of normal mouse mammary tissues and mammary adenocarcinoma to cleave rat prolactin. Proceedings of the Society for Experimental Biology and Medicine 208:283-287.
Baldocchi RA, Tan L, King DS, Nicoll CS. 1993. Mass-spectrometric analysis of the fragments produced by cleavage and reduction of rat prolactin - evidence that the cleaving enzyme is cathepsin-d. Endocrinology 133:935-938.
Bernard V, Young J, Chanson P, Binart N. 2015. New insights in prolactin: pathological implications. Nature Reviews Endocrinology 11:265-275.
Bernichtein S, Touraine P, Goffin V. 2010. New concepts in prolactin biology. Journal of Endocrinology 206:1-11.
Berry TU. 2003. Encyclopedia of hormones. Library Journal 128:68-68.
Binart N, Bachelot A, Bouilly J. 2010. Impact of prolactin receptor isoforms on reproduction. Trends in Endocrinology and Metabolism 21:362-368.
Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. 1998. Prolactin (PRL) and its receptor: Actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocrine Reviews 19:225-268.
Bollen IAE, Van Deel ED, Kuster DWD, Van Der Velden J. 2015. Peripartum cardiomyopathy and dilated cardiomyopathy: different at heart. Frontiers in Physiology 5 (art. 531).
Borza CM, Pozzi A, Borza DB, Pedchenko V, Hellmark T, Hudson BG, Zent R. 2006. Integrin alpha 3 beta 1, a Novel Receptor for alpha 3(IV) noncollagenous domain and a trans-dominant inhibitor for integrin alpha v beta 3. Journal of Biological Chemistry 281:20932-20939.
Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JWY, Shen AYJ. 2007. Incidence, mortality, and racial differences in peripartum cardiomyopathy. American Journal of Cardiology 100:302-304.
Brasier AR. 2010. The nuclear factor-kappa B-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovascular Research 86:211-218.
Brooks CL, Kim BG, Aphale P, Kleeman BE, Johnson GC. 1990. Phosphorylated variant of bovine prolactin. Molecular and Cellular Endocrinology 71:117-123.
Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. 2005. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. American Journal of Obstetrics and Gynecology 193:363-365.
Caron MG, Beaulieu M, Raymond V, Gagne B, Drouin J, Lefkowitz RJ, Labrie F. 1978. Dopaminergic receptors in anterior-pituitary gland - correlation of h-3 dihydroergocryptine binding with dopaminergic control of prolactin-release. Journal of Biological Chemistry 253:2244-2253.
Chen TJ, Kuo CB, Tsai KF, Liu JW, Chen DY, Walker AM. 1998. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 139:609-616.
Clapp C. 1987. Analysis of the proteolytic cleavage of prolactin by the mammary-gland and liver of the rat - characterization of the cleaved and 16k forms. Endocrinology 121:2055-2064.
Clapp C, Aranda J, Gonzalez C, Jeziorski MC, de la Escalera GM. 2006. Vasoinhibins: endogenous regulators of angiogenesis and vascular function. Trends in Endocrinology and Metabolism 17:301-307.
Clapp C, Sears PS, Nicoll CS. 1989. Binding-studies with intact rat prolactin and a 16k fragment of the hormone. Endocrinology 125:1054- 1059.
Clapp C, Thebault S, de la Escalera GM. 2008. Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland. Journal of Mammary Gland Biology and Neoplasia 13:55-67.
Clapp C, Thebault S, Jeziorski MC, De la Escalera GM. 2009. Peptide Hormone Regulation of Angiogenesis. Physiological Reviews 89:1177-1215.
Clapp C, Weiner RI. 1992. A specific, high-affinity, saturable binding- site for the 16-kilodalton fragment of prolactin on capillary endothelial-cells. Endocrinology 130:1380-1386.
Compton MM, Witorsch RJ. 1984. Proteolytic degradation and modification of rat prolactin by subcellular-fractions of the rat ventral prostate-gland. Endocrinology 115:476-484.
Cooke NE, Coit D, Shine J, Baxter JD, Martial JA. 1981. Human-prolactin - cdna structural-analysis and evolutionary comparisons. Journal of Biological Chemistry 256:4007-4016.
Cooke NE, Coit D, Weiner RI, Baxter JD, Martial JA. 1980. Structure of cloned dna complementary to rat prolactin messenger-rna. Journal of Biological Chemistry 255:6502-6510.
Corbacho AM, de las Escalera GM, Clapp C. 2002. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. Journal of Endocrinology 173:219-238.
Corbacho AM, Macotela Y, Nava G, Torner L, Duenas Z, Noris G, Morales MA, de la Escalera GM, Clapp C. 2000. Human umbilical vein endothelial cells express multiple prolactin isoforms. Journal of Endocrinology 166:53-62.
Cruz-Soto ME, et al. 2009. Cathepsin D Is the Primary Protease for the Generation of Adenohypophyseal Vasoinhibins: Cleavage Occurs within the Prolactin Secretory Granules. Endocrinology 150:5446-5454.
Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D. 2005. NAD(P)H oxidase 4 mediates transforming growth factor-beta 1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circulation Research 97:900-907.
Demakis JG, Rahimtoola SH, Sutton GC, Meadows WR, Szanto PB, Tobin JR, Gunnar RM. 1971. Natural course of peripartum cardiomyopathy. Circulation 44:1053-+.
Dhanabal M, Ramchandran R, Waterman MJF, Lu H, Knebelmann B, Segal M, Sukhatme VP. 1999. Endostatin induces endothelial cell apoptosis. Journal of Biological Chemistry 274:11721-11726.
Digtyar AV, Pozdnyakova NV, Feldman NB, Lutsenko SV, Severin SE. 2007. Endostatin: Current concepts about its biological role and mechanisms of action. Biochemistry-Moscow 72:235-246.
Du LL, Wu W. 2012. A mimic of phosphorylated prolactin induces apoptosis by activating AP-1 and upregulating p21/waf1 in human prostate cancer PC3 cells. Oncology Letters 4:1064-1068.
Emanuele NV, Jurgens JK, Halloran MM, Tentler JJ, Lawrence AM, Kelley MR. 1992. The rat prolactin gene is expressed in brain-tissue - detection of normal and alternatively spliced prolactin messenger- rna. Molecular Endocrinology 6:35-42.
Erdmann S, Ricken A, Merkwitz C, Struman I, Castino R, Hummitzsch K, Gaunitz F, Isidoro C, Martial J, Spanel-Borowski K. 2007. The expression of prolactin and its cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle. American Journal of Physiology-Endocrinology and Metabolism 293:E1365-E1377.
Faust PL, Kornfeld S, Chirgwin JM. 1985. Cloning and sequence-analysis of cdna for human cathepsin-d. Proceedings of the National Academy of Sciences of the United States of America 82:4910-4914.
Ferrara N, Clapp C, Weiner R. 1991. The 16k fragment of prolactin specifically inhibits basal or fibroblast growth-factor stimulated growth of capillary endothelial-cells. Endocrinology 129:896-900.
Floquet N, Pasco S, Ramont L, Derreumaux P, Laronze JY, Nuzillard JM, Maquart FX, Alix AJP, Monboisse JC. 2004. The antitumor properties of the alpha 3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. Journal of Biological Chemistry 279:2091-2100.
Forster O, Hilfiker-Kleiner D, Ansari AA, Sundstrom JB, Libhaber E, Tshani W, Becker A, Yip A, Klein G, Sliwa K. 2008. Reversal of IFN- gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. European Journal of Heart Failure 10:861-868.
Freeman ME, Kanyicska B, Lerant A, Nagy G. 2000. Prolactin: structure, function, and regulation of secretion. Physiological Reviews 80:1523- 1631.
Garcia C, et al. 2008. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. Journal of Clinical Investigation 118:2291-2300.
Garcia C, Nunez-Anita RE, Thebault S, Zamarripa DA, Jeziorsky MC, de la Escalera GM, Clapp C. 2014. Requirement of phosphorylatable endothelial nitric oxide synthase at Ser-1177 for vasoinhibin- mediated inhibition of endothelial cell migration and proliferation in vitro. Endocrine 45:263-270.
Garcia-Mata R, Burridge K. 2007. Catching a GEF by its tail. Trends in Cell Biology 17:36-43.
Ge GX, Fernandez CA, Moses MA, Greenspan DS. 2007. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proceedings of the National Academy of Sciences of the United States of America 104:10010-10015.
Ghosh S, May MJ, Kopp EB. 1998. NF-kappa B and rel proteins: Evolutionarily conserved mediators of immune responses. Annual Review of Immunology 16:225-260.
Gonzalez C, et al. 2007. Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Laboratory Investigation 87:1009-1017.
Greenan JR, Balden E, Ho TWC, Walker AM. 1989. Biosynthesis of the secreted 24-k isoforms of prolactin. Endocrinology 125:2041-2048.
Guzman EA, Langowski JL, De Guzman A, Muller HK, Walker AM, Owen LB. 2008. S179D prolactin diminishes the effects of UV light on epidermal gamma delta T cells. Molecular and Cellular Endocrinology 280:6-12.
Haghikia A, et al. 2013. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Research in Cardiology 108 (art. 366).
Halkein J, et al. 2013. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. Journal of Clinical Investigation 123:2143-2154.
Harigaya T, Komori M, Kawakami T, Watanabe H, Abe M. 1997. Expression of prolactin gene in mouse placenta during late pregnancy: Detection of mRNA and its translation product. Endocrine Journal 44:155-161.
Hilfiker-Kleiner D, et al. 2007. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128:589-600.
Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. 2001. Alpha- smooth muscle actin expression upregulates fibroblast contractile activity. Molecular Biology of the Cell 12:2730-2741.
Ho TWC, Leong FS, Olaso CH, Walker AM. 1993. Secretion of specific nonphosphorylated and phosphorylated rat prolactin isoforms at different stages of the estrous-cycle. Neuroendocrinology 58:160-165.
Horiguchi K, Naito JI, Ishida M, Harigaya T. 2007a. The effect of estrogen on phosphorylation of prolactin in the mouse pituitary gland. Journal of Reproduction and Development 53:515-523.
Horiguchi K, Fukuta S, Yoshida M, Kosugi T, Naito JI, Ishida M, Harigaya T. 2007b Estrogen regulates the serum level of phosphorylated prolactin in mice. Journal of Reproduction and Development 53:915- 922.
Horiguchi K, Yagi S, Ono K, Nishiura Y, Tanaka M, Ishida M, Harigaya T. 2004. Prolactin gene expression in mouse spleen helper T cells. Journal of Endocrinology 183:639-646.
Horne BD, et al. 2011. Genome-Wide Significance and Replication of the Chromosome 12p11.22 Locus Near the PTHLH Gene for Peripartum Cardiomyopathy. Circulation-Cardiovascular Genetics 4:359-U363.
Humphries JD, Byron A, Humphries MJ. 2006. Integrin ligands at a glance. Journal of Cell Science 119:3901-3903.
Ishida M, Maehara M, Watanabe T, Yanagisawa Y, Takata Y, Nakajima R, Suzuki M, Harigaya T. 2014. Vasoinhibins, N-terminal mouse prolactin fragments, participate in mammary gland involution. Journal of Molecular Endocrinology 52:279-287.
Jugdutt BI. 2003. Ventricular remodeling after infarction and the extracellular collagen matrix - When is enough enough? Circulation 108:1395-1403.
Jung JH, Traugh JA. 2005. Regulation of the interaction of Pak2 with Cdc42 via autophosphorylation of serine 141. Journal of Biological Chemistry 280:40025-40031.
Kamiya CA, Kitakaze M, Ishibashi-Ueda H, Nakatani S, Murohara T, Tomoike H, Ikeda T. 2011. Different Characteristics of Peripartum Cardiomyopathy Between Patients Complicated With and Without Hypertensive Disorders - Results From the Japanese Nationwide Survey of Peripartum Cardiomyopathy. Circulation Journal 75:1975-1981.
Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, Wakefield LM, Letterio JJ, Wynn TA. 2004. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. Journal of Immunology 173:4020-4029.
Keeler C, Dannies PS, Hodsdon ME. 2003. The tertiary structure and backbone dynamics of human prolactin. Journal of Molecular Biology 328:1105-1121.
Khurana S, Liby K, Buckley AR, Ben-Jonathan N. 1999. Proteolysis of human prolactin: Resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin. Endocrinology 140:4127-4132.
Kim BG, Brooks CL. 1993. Isolation and characterization of phosphorylated bovine prolactin. Biochemical Journal 296:41-47.
Kohmoto K, Tsunasawa S, Sakiyama F. 1984. Complete amino-acid-sequence of mouse prolactin. European Journal of Biochemistry 138:227-237.
Krown KA, Wang YF, Ho TWC, Kelly PA, Walker AM. 1992. Prolactin isoform- 2 as an autocrine growth-factor for gh3 cells. Endocrinology 131:595- 602.
Lan HY. 2011. Diverse Roles of TGF-beta/Smads in Renal Fibrosis and Inflammation. International Journal of Biological Sciences 7:1056- 1067.
Lee RCH, Walters JA, Reyland ME, Anderson SM. 1999. Constitutive activation of the prolactin receptor results in the induction of growth factor-independent proliferation and constitutive activation of signaling molecules. Journal of Biological Chemistry 274:10024- 10034.
Lee SH, Kunz L, Lin SH, Yu-Lee LY. 2007. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1- Pak1 signaling pathway. Cancer Research 67:11045-11053.
Lee SH, et al. 2005. 16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway. Cancer Research 65:7984-7992.
Li YJ, Tan XY, Dai CS, Stolz DB, Wang D, Liu YH. 2009. Inhibition of Integrin-Linked Kinase Attenuates Renal Interstitial Fibrosis. Journal of the American Society of Nephrology 20:1907-1918.
Lijnen HR, Ugwu F, Bini A, Collen D. 1998. Generation of an angiostatin- like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37:4699-4702.
Liu JM, et al. 2014. The Correlation between Peripartum Cardiomyopathy and Autoantibodies against Cardiovascular Receptors. Plos One 9 (art. e86770).
Macotela Y, Aguilar MB, Guzman-Morales J, Rivera JC, Zermeno C, Lopez- Barrera F, Nava G, Lavalle C, de la Escalera GM, Clapp C. 2006. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. Journal of Cell Science 119:1790-1800.
Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO, Kalluri R. 2002. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295:140-143.
Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. 2010. Interleukin 6 Mediates Myocardial Fibrosis, Concentric Hypertrophy, and Diastolic Dysfunction in Rats. Hypertension 56:225-231.
Meuris S, Verloes A, Robyn C. 1983. Immunocytochemical localization of prolactin-like immunoreactivity in rat pancreatic-islets. Endocrinology 112:2221-2223.
Mittra I. 1980. A novel cleaved prolactin in the rat pituitary .1. biosynthesis, characterization and regulatory control. Biochemical and Biophysical Research Communications 95:1750-1759.
Nagae M, Re S, Mihara E, Nogi T, Sugita Y, Takagi J. 2012. Crystal structure of alpha 5 beta 1 integrin ectodomain: Atomic details of the fibronectin receptor. Journal of Cell Biology 197:131-140.
Nakajima R, Nakamura E, Harigaya T. 2017. Vasoinhibin, an N-terminal Prolactin Fragment, Directly Inhibits Cardiac Angiogenesis in Three- dimensional Heart Culture. Frontiers in Endocrinology 8 (art. 4).
Nermut MV, Green NM, Eason P, Yamada SS, Yamada KM. 1988. Electron- microscopy and structural model of human fibronectin receptor. Embo Journal 7:4093-4099.
Ntusi NBA, Mayosi BM. 2009. Aetiology and risk factors of peripartum cardiomyopathy: A systematic review. International Journal of Cardiology 131:168-179.
Oconnell JB, Costanzonordin MR, Subramanian R, Robinson JA, Wallis DE, Scanlon PJ, Gunnar RM. 1986. Peripartum cardiomyopathy - clinical, hemodynamic, histologic and prognostic characteristics. Journal of the American College of Cardiology 8:52-56.
Oetting WS, Tuazon PT, Traugh JA, Walker AM. 1986. Phosphorylation of prolactin. Journal of Biological Chemistry 261:1649-1652.
Oga T, et al. 2009. Prostaglandin F-2 alpha receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nature Medicine 15:1426-U1412.
Pan XD, Chen ZP, Huang R, Yao YY, Ma GS. 2013. Transforming Growth Factor beta(1) Induces the Expression of Collagen Type I by DNA Methylation in Cardiac Fibroblasts. Plos One 8 (art. e60335).
Patten IS, et al. 2012. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485:333-U376.
Patterson BC, Sang QXA. 1997. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B type IV collagenase (MMP-9). Journal of Biological Chemistry 272:28823-28825.
Perimenis P, et al. 2014. Placental antiangiogenic prolactin fragments are increased in human and rat maternal diabetes. Biochimica Et Biophysica Acta-Molecular Basis of Disease 1842:1783-1793.
Piwnica D, Touraine P, Struman I, Tabruyn S, Bolbach G, Clapp C, Martial JA, Kelly PA, Goffin V. 2004. Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: Study of their antiangiogenic properties and physiological relevance. Molecular Endocrinology 18:2522-2542.
Ricke-Hoch M, Bultmann I, Stapel B, Condorelli G, Rinas U, Sliwa K, Scherr M, Hilfiker-Kleiner D. 2014. Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress. Cardiovascular Research 101:587-596.
Riddle O, R.W.Bates, S.W.dykshorn. 1933. The preparation, identification and assay of prolactin-a hormone of anterior pituitary. Amer.J.physiol 105: 191-216
Riecher-Rossler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS, Malik P, Fleischhacker WW, Grp ES. 2013. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychological Medicine 43:2571-2582.
Robles JP, Zamora M, Velasco-Bolom JL, Tovar M, Garduno-Juarez R, Bertsch T, de la Escalera GM, Triebel J, Clapp C. 2018. Vasoinhibin comprises a three-helix bundle and its antiangiogenic domain is located within the first 79 residues. Scientific Reports 8 (art. 17111).
Rojas AM, Fuentes G, Rausell A, Valencia A. 2012. The Ras protein superfamily: Evolutionary tree and role of conserved amino acids. Journal of Cell Biology 196:189-201.
Rose-John S, Neurath MF. 2004. IL-6 trans-signaling: The heat is on.Immunity 20:2-4.
Russell J, Sherwood LM, Kowalski K, Schneider AB. 1981. Recombinant hormones from fragments of human growth-hormone and human placental- lactogen. Journal of Biological Chemistry 256:296-300.
Sabatel C, Cornet AM, Tabruyn SP, Malvaux L, Castermans K, Martial JA, Struman I. 2010. Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Molecular Cancer 9 (art. 231).
Saha RN, Jana M, Pahan K. 2007. MAPK p38 regulates transcriptional activity of NF-kappa B in primary human astrocytes via acetylation of p65. Journal of Immunology 179:7101-7109.
Sanderson JE, Lai KB, Shum IOL, Wei S, Chow LTC. 2001. Transforming growth factor-beta(1) expression in dilated cardiomyopathy. Heart 86:701-702.
Sankoorikal BJ, Zhu YL, Hodsdon ME, Lolis E, Dannies PS. 2002. Aggregation of human wild-type and H27A-prolactin in cells and in solution: Roles of Zn2+, Cu2+, and pH. Endocrinology 143:1302-1309. Shiokawa S, Yoshimura Y, Sawa H, Nagamatsu S, Hanashi H, Sakai K, Ando M, Nakamura Y. 1999. Functional role of Arg-Gly-Asp (RGD)-binding sites on beta(1) integrin in embryo implantation using mouse blastocysts and human decidua. Biology of Reproduction 60:1468-1474.
Sinha YN. 1995. Structural variants of prolactin - occurrence and physiological significance. Endocrine Reviews 16:354-369.
Sinha YN, Gilligan TA. 1984. A cleaved form of prolactin in the mouse pituitary-gland - identification and comparison of invitro synthesis and release in strains with high and low incidences of mammary-tumors. Endocrinology 114:2046-2053.
Sinha YN, Gilligan TA, Lee DW, Hollingsworth D, Markoff E. 1985. Cleaved prolactin - evidence for its occurrence in human pituitary-gland and plasma. Journal of Clinical Endocrinology & Metabolism 60:239-243.
Sliwa K, et al. 2010. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure 12:767-778.
Souders CA, Bowers SLK, Baudino TA. 2009. Cardiac Fibroblast The Renaissance Cell. Circulation Research 105:1164-1176.
Steinmetz RW, Grant AL, Malven PV. 1993. Transcription of prolactin gene in milk secretory-cells of the rat mammary-gland. Journal of Endocrinology 136:271-&.
Struman I, Bentzien F, Lee HY, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA. 1999. Opposing actions of intact and N-terminal fragments of the human prolactin growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 96:1246-1251.
Sudhakar A, Sugimoto H, Yang CQ, Lively J, Zeisberg M, Kalluri R. 2003. Human tumstatin land human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proceedings of the National Academy of Sciences of the United States of America 100:4766-4771.
Tabruyn SP, Nguyen NQN, Cornet AM, Martial JA, Struman I. 2005. The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G(0)-G(1) and the G(2)-M phases. Molecular Endocrinology 19:1932-1942.
Tabruyn SP, Sorlet CM, Rentier-Delrue F, Bours V, Weiner RI, Martial JA, Struman I. 2003. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappa B. Molecular Endocrinology 17:1815-1823.
Tarui T, Miles LA, Takada Y. 2001. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. Journal of Biological Chemistry 276:39562-39568.
Tcherkezian J, Lamarche-Vane N. 2007. Current knowledge of the large RhoGAP family of proteins. Biology of the Cell 99:67-86.
Triebel J, Huefner M, Ramadori G. 2009. Investigation of prolactin- related vasoinhibin in sera from patients with diabetic retinopathy. European Journal of Endocrinology 161:345-353.
Ueda E, Ozerdem U, Chen YH, Yao M, Huang KT, Sun HQ, Martins-Green M, Bartolini P, Walker AM. 2006. A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocrine-Related Cancer 13:95-111.
Urbich C, Reissner A, Chavakis E, Dernbach E, Haendeler J, Fleming I, Zeiher AM, Kaszkin M, Dimmeler S. 2002. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. Faseb Journal 16:706-+.
Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA. 2001. Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: New insight into the role of tissue inhibitors of matrix metalloproteinases. Journal of Immunology 167:7017-7026.
van Spaendonck-Zwarts KY, et al. 2014. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. European Heart Journal 35:2165-2173.
Vara JAF, Caceres AD, Silva A, Martin-Perez J. 2001. Src family kinases are required for prolactin induction of cell proliferation. Molecular Biology of the Cell 12:2171-2183.
Volk SW, Wang Y, Mauldin EA, Liechty KW, Adams SL. 2011. Diminished Type III Collagen Promotes Myofibroblast Differentiation and Increases Scar Deposition in Cutaneous Wound Healing. Cells Tissues Organs 194:25-37.
Volk SW, Wang YJ, Cohen AJ, Liechty KW, Adams SL. 2009. Diminished type iii collagen expression improves wound contraction and promotes myofibroblast differentiation. Wound Repair and Regeneration 17:A22- A22.
Walker AM. 2007. S179D prolactin: Antagonistic agony! Molecular and Cellular Endocrinology 276:1-9.
Wang YF, Liu JW, Mamidi M, Walker AM. 1996. Identification of the major site of rat prolactin phosphorylation as serine 177. Journal of Biological Chemistry 271:2462-2469.
Wang YF, Walker AM. 1993. Dephosphorylation of standard prolactin produces a more biologically-active molecule - evidence for antagonism between nonphosphorylated and phosphorylated prolactin in the stimulation of nb-2 cell-proliferation. Endocrinology 133:2156- 2160.
Weber KT, Brilla CG. 1992. Factors associated with reactive and reparative fibrosis of the myocardium. Basic Research in Cardiology 87:291-301.
Wicks JR, Brooks CL. 1999. Prolactin kinase activity in bovine anterior pituitary sub-cellular fractions. Molecular and Cellular Endocrinology 147:125-132.
Wong VLY, Compton MM, Witorsch RJ. 1986. proteolytic modification of rat prolactin by subcellular-fractions of the lactating rat mammary-gland. Biochimica Et Biophysica Acta 881:167-174.
Wynn TA, Ramalingam TR. 2012. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nature Medicine 18:1028-1040.
Xie WJ, He Y, Huo D, Huang YF, Wu W. 2010. A mimic of phosphorylated prolactin inhibits human breast cancer cell proliferation via upregulation of p21 waf1. Medical Oncology 27:1340-1345.
Xu XL, Wu W, Williams V, Khong A, Chen YH, Deng CH, Walker AM. 2003. Opposite effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin on morphology and the expression of prostate specific genes in the normal rat prostate. Prostate 54:25-33.
Zamorano M, et al. 2014. Pro lactin-derived vasoinhibins increase anxiety- and depression-related behaviors. Psychoneuroendocrinology 44:123-132.